1.Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?.
Intestinal Research 2016;14(4):293-294
No abstract available.
Inflammatory Bowel Diseases*
;
Leukocyte L1 Antigen Complex*
2.Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?.
Intestinal Research 2016;14(4):293-294
No abstract available.
Inflammatory Bowel Diseases*
;
Leukocyte L1 Antigen Complex*
3.Optimal Usage of Fecal Calprotectin for Intestinal Diseases.
Korean Journal of Medicine 2018;93(4):364-368
No abstract available.
Intestinal Diseases*
;
Leukocyte L1 Antigen Complex*
4.Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases.
Intestinal Research 2018;16(4):507-508
No abstract available.
Humans
;
Inflammatory Bowel Diseases*
;
Leukocyte L1 Antigen Complex*
6.Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis.
Ji Young CHANG ; Jae Hee CHEON
Gut and Liver 2018;12(2):117-118
No abstract available.
Colitis, Ulcerative*
;
Humans
;
Leukocyte L1 Antigen Complex*
;
Ulcer*
7.The Usefulness of Fecal Calprotectin in Differentiating between Functional and Organic Bowel Diseases: Application in Pediatric Constipation Patients.
The Korean Journal of Gastroenterology 2013;62(5):261-262
No abstract available.
Constipation/*diagnosis
;
Female
;
Hirschsprung Disease/*diagnosis
;
Humans
;
Leukocyte L1 Antigen Complex/*analysis
;
Male
8.Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
Kai Chun WU ; Zhi Hua RAN ; Xiang GAO ; Minhu CHEN ; Jie ZHONG ; Jian Qiu SHENG ; Michael A KAMM ; Simon TRAVIS ; Kori WALLACE ; Nael M MOSTAFA ; Marisa SHAPIRO ; Yao LI ; Roopal B THAKKAR ; Anne M ROBINSON
Intestinal Research 2016;14(2):152-163
BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored. RESULTS: Mean adalimumab serum concentrations during the induction phase were 13.9-18.1 µg/mL (160/80 mg group) and 7.5-9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups. CONCLUSIONS: Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.
Adult
;
Asian Continental Ancestry Group*
;
Crohn Disease*
;
Humans
;
Leukocyte L1 Antigen Complex
;
Pharmacokinetics
9.Analysis of N-terminal amino acid sequence of 12 000-protein in gingival crevicular fluid and its clinical significance.
Rongji WANG ; Huanxin MENG ; Zhibin CHEN ; Caifang CAO
Chinese Journal of Stomatology 2002;37(4):297-299
<b>OBJECTIVESb>To study the essence of N-terminal amino acid sequence of 12 000-protein in gingival crevicular fluid (GCF).
<b>METHODSb>GCF samples from patients with RPP and AP were collected. 12 000-protein was separated by SDS-PAGE and transformed to PVDF by electronic transformation. The aim band was cut to be analyzed in 491 Protein Sequencer.
<b>RESULTSb>The first ten of N-terminal amino acid sequence of 12 000-protein in GCF was Met, Leu, Thr, Glu, Leu, Glu, Lys, Ala, Leu, Asn. Through checking up in MS-Edman, the sequence was similar to "Ca binding protein, MRP8" which is the light subunit of Calprotectin.
<b>CONCLUSIONSb>Calprotectin is a major protein in granulocytes and monocytes, and is related to many inflammatory diseases, maybe served as a effective marker for evaluating the inflammation of periodontium.
Amino Acid Sequence ; Electrophoresis, Polyacrylamide Gel ; Gingival Crevicular Fluid ; chemistry ; Humans ; Leukocyte L1 Antigen Complex ; Periodontium
10.Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring.
Shu Chen WEI ; Chien Chih TUNG ; Meng Tzu WENG ; Jau Min WONG
Intestinal Research 2018;16(4):546-553
BACKGROUND/AIMS: Fecal calprotectin (fC) level is a predictive marker of mucosal healing for patients with inflammatory bowel disease (IBD). Home fC tests are now available. We evaluated the performance of the smartphone-based IBDoc home testing system in patients with IBD and obtained their feedback as an objective patient-reported outcome. METHODS: This prospective study enrolled consecutive patients with IBD in clinical remission. fC in the same stool sample was assessed by using both the laboratory test (Quantum Blue calprotectin test) and home test (IBDoc). The correlation between the 2 tests was analyzed using the Pearson method. In addition, the patients were asked to fill a questionnaire based on their experience. RESULTS: Fifty-one patients with IBD (68 tests and 49 questionnaires) were included. The correlation between Quantum Blue test and IBDoc was good (r=0.776, P < 0.0001). After the test, 56% patients found IBDoc easy to perform, and 96% were satisfied with it. Thirty-nine patients (80%) had a strong (>70%) probability to use it for future monitoring if the price was acceptable. By using 250 μg/g as the cutoff, the agreement between home test and laboratory results was 80%, and by using 600 μg/g as the cutoff, the agreement increased to 92%. CONCLUSIONS: The correlation between the laboratory and home tests was good. Most patients found the home test to be feasible and easy to use and preferred it over laboratory test and endoscopy for monitoring. Therefore, the home test could be used as an objective patient-reported outcome.
Colitis, Ulcerative
;
Crohn Disease
;
Endoscopy
;
Humans
;
Inflammatory Bowel Diseases*
;
Leukocyte L1 Antigen Complex*
;
Methods
;
Prospective Studies
Result Analysis
Print
Save
E-mail